default author photo

Xiaoyun Yang

Guangzhou Laboratory

Guangzhou

China

SCHOLARLY PAPERS

1

DOWNLOADS

228

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b Trial

Number of pages: 25 Posted: 15 Feb 2023
Yixing People's Hospital, Nanjing Medical University, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, Yixing People's Hospital, CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Laboratory, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Medical University - State Key Laboratory of Respiratory Disease and Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology
Downloads 228 (336,244)

Abstract:

Loading...

SARS-CoV-2, Omicron, heterologous booster, homologous booster, mRNA vaccine CS-2034, safety, immunogenicity